- Home
- TYRA vs NRK Comparison
TYRA vs NRK Comparison
Compare TYRA & NRK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TYRA
- NRK
- Stock Information
- Founded
- TYRA 2018
- NRK 2002
- Country
- TYRA United States
- NRK United States
- Employees
- TYRA N/A
- NRK N/A
- Industry
- TYRA Biotechnology: Pharmaceutical Preparations
- NRK Trusts Except Educational Religious and Charitable
- Sector
- TYRA Health Care
- NRK Finance
- Exchange
- TYRA Nasdaq
- NRK Nasdaq
- Market Cap
- TYRA 844.2M
- NRK 884.6M
- IPO Year
- TYRA 2021
- NRK N/A
- Fundamental
- Price
- TYRA $14.86
- NRK $10.14
- Analyst Decision
- TYRA Strong Buy
- NRK
- Analyst Count
- TYRA 5
- NRK 0
- Target Price
- TYRA $31.20
- NRK N/A
- AVG Volume (30 Days)
- TYRA 238.5K
- NRK 187.3K
- Earning Date
- TYRA 11-14-2025
- NRK 01-01-0001
- Dividend Yield
- TYRA N/A
- NRK 4.10%
- EPS Growth
- TYRA N/A
- NRK N/A
- EPS
- TYRA N/A
- NRK N/A
- Revenue
- TYRA N/A
- NRK N/A
- Revenue This Year
- TYRA N/A
- NRK N/A
- Revenue Next Year
- TYRA N/A
- NRK N/A
- P/E Ratio
- TYRA N/A
- NRK N/A
- Revenue Growth
- TYRA N/A
- NRK N/A
- 52 Week Low
- TYRA $6.42
- NRK $8.95
- 52 Week High
- TYRA $17.78
- NRK $11.09
- Technical
- Relative Strength Index (RSI)
- TYRA 56.47
- NRK 57.34
- Support Level
- TYRA $13.75
- NRK $10.04
- Resistance Level
- TYRA $16.05
- NRK $10.19
- Average True Range (ATR)
- TYRA 0.82
- NRK 0.08
- MACD
- TYRA 0.01
- NRK -0.01
- Stochastic Oscillator
- TYRA 54.35
- NRK 82.61
About TYRA Tyra Biosciences Inc.
Tyra Biosciences Inc is a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology. The company's in-house precision medicine platform, SNAP, enables rapid and precise drug design through iterative molecular SNAPshots that help to design and predict which product candidates may demonstrate the highest potency, selectivity, and tolerability in the clinic. The various drug candidates in the company's product pipeline are TYRA-300, TYRA-200, and TYRA-430: three clinical-stage, novel small molecules designed to overcome the toxicity and resistance liabilities of first-generation pan-FGFR inhibitors.
About NRK Nuveen New York AMT-Free Quality Municipal Income Fund
Nuveen New York AMT-Free Quality Municipal Income Fund is a closed-end investment company. Its investment objective is to provide current income exempt from regular federal, New York State, and New York City income taxes and from the federal alternative minimum tax applies to individuals and to enhance portfolio value relative to the municipal bond market by investing in tax-exempt municipal bonds that the Fund's investment adviser believes are underrated or undervalued or that represent municipal market sectors that are undervalued.